Glucotrack’s Continuous Blood Glucose Monitor (CBGM) will provide real-time glucose readings to drive insulin delivery decisions for the bionic pancreas system. “We are committed to the goal ...

approval for continuous blood glucose monitoring (CBGM) technology from FDA expected in Q4 2025 Rutherford, NJ, March 31, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack ...

The company’s part in this is to contribute its investigational continuous blood glucose monitor (CBGM). This provides real-time glucose readings to drive insulin delivery decisions for the bionic ...

Glucotrack’s Continuous Blood Glucose Monitor (CBGM) will provide real-time glucose readings to drive insulin delivery decisions for the bionic pancreas system. “We are committed to the goal of ...

Tidepool announced today that it secured a new certification for its open-source quality management system, known as qmsOS. Palo Alto, California-based Tidepool, a non-profit diabetes data management ...

Hyperfine (Nasdaq:HYPR) announced that it enrolled the initial patients in a study of its portable MRI technology for neurological evaluation. The NEURO PMR evaluates the Swoop portable magnetic ...

Phantom Neuro announced today that it raised $19 million in a Series A funding round to support its neural interface technology. Ottobock, a major company in the fields of prosthetics, orthotics ...